Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Re test of last years lows?

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Jan 26, 2021 1:28pm

147 Views

Post# 32388704

RE:RE:RE:RE:Re test of last years lows?

It doesn't help when you ignore the bigger more important firms to do a sweetheart deal (at the time) with your friends you still have at NB. There were rumours when they did their prior financing that they pissed off the wrong people back then too. I guess they don't learn. I'm curious to see the next short report. I think someone is sending a clear message to management

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo